Tregalizumab, a humanized IgG1-type monoclonal antibody targeting CD4, selectively activates regulatory T cells (Tregs) with suppressive functions in vitro and has potential applications in researching autoimmune diseases (due to inadequate Treg activity) and allergies [1] [2] [3].

Tregalizumab 能够激活调节性T细胞的抑制功能，并以剂量依赖性的方式抑制用破伤风类毒素刺激的分离PBMC的增殖与细胞因子分泌。此外，在处理PBMC的情况下，Tregalizumab (0-30 µg/mL; 18小时)可诱导T细胞CD4水平的下调，特别是在炎症部位表现尤为明显。